# High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

> **NCT03070717** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 153 (actual)

## Conditions studied

- Pathologic Myopia

## Interventions

- **PROCEDURE:** Observation & Diagnosis

## Key facts

- **NCT ID:** NCT03070717
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-12
- **Primary completion:** 2019-05-23
- **Final completion:** 2019-05-23
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070717, "High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03070717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*